Dr. Homan has advanced numerous life science companies from inception through maturity. He has been a Corporate Executive, Founder, Director, CEO, Investor and Advisor to pharmaceutical, biotech, medical device, and digital health companies.
He served as CEO of Urovalve, Inc., and Ingenion Medical, Inc., that were focused on urinary tract disorders. The Urovalve team secured five NIH SBIR grants as well as 2 grants from the New Jersey Commission of Science and Technology (total = $1.3 M). He has also held leadership roles at Sterling Health and Boots Company in new product development, clinical, regulatory, sales, and strategic marketing supported commercialization of dozens of international products for major OTC brands including Bayer, Neurofen, Strepsils, Midol.
Dr. Homan has always been committed to advancing innovation. He advances innovation as an Advisory Board Member for TRx and BioMedx Accelerators at Columbia University Medical Center. He is an active angel investor through Keiretsu Forum Mid-Atlantic where he serves as the Chapter President of the North Jersey group. Keiretsu Forum is consistently ranked as the #1 most active angel investor network by Angel Research Institute.
In 2021, Dr. Homan combined several passions by Co-Founding MetasTx LLC, a company driven to develop novel drugs to treat and prevent metastatic cancers. Dr. Homan serves as CEO along side Scientific Co-Founders Dr Somanath Shenoy and Dr. Brian Cumming. The team has secured $3.58M in grant funding and recently launched their first round of funding that will accelerate IND-enabling studies.
Metastatic cancer remains one of oncology’s most stubborn problems. MetasTx is developing a first-in-class small-molecule therapy against a unique target that inhibits cancer’s ability to metastasize.
In this webinar, Harvey Homan, PhD, MBA, co-Founder and CEO and of MetasTx, LLC invited Sandip Prasad, MD, MPhil, Surgical Director of Urologic Oncology and Co-Chair of Urology at Atlantic Health System/ Morristown Medical Center, to join him in a conversation about why understanding and getting regular screenings for prostate cancer is critical. Early detection offers a patient more treatment options, a better quality of life, and an extension of life expectancy. Dr. Homan and Dr. Prasad walk through the myths and assumptions many men make about prostate cancer, the advanced treatments available today, and the innovative treatments that are on the near horizon to extend and improve the Quality of Life for patients with advanced metastatic prostate cancer. Dr. Prasad and Dr. Homan share a passion for early screening and innovative treatments. Further, Harvey shares that he is living with prostate cancer. His passion for improving a patient's quality...